Champlain Investment Partners LLC Has $134.44 Million Holdings in Exact Sciences Corporation $EXAS

Champlain Investment Partners LLC grew its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 12.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,529,820 shares of the medical research company’s stock after buying an additional 282,825 shares during the quarter. Champlain Investment Partners LLC owned approximately 1.34% of Exact Sciences worth $134,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in EXAS. Great Lakes Advisors LLC raised its position in Exact Sciences by 3.7% during the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after acquiring an additional 178 shares in the last quarter. Nissay Asset Management Corp Japan ADV increased its stake in shares of Exact Sciences by 0.8% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,432 shares of the medical research company’s stock worth $971,000 after purchasing an additional 187 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of Exact Sciences by 0.4% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company’s stock valued at $3,127,000 after purchasing an additional 217 shares in the last quarter. IFP Advisors Inc lifted its stake in shares of Exact Sciences by 6.5% in the 2nd quarter. IFP Advisors Inc now owns 4,466 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 273 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in shares of Exact Sciences by 37.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,018 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 275 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Insider Buying and Selling

In other Exact Sciences news, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the sale, the director directly owned 57,962 shares in the company, valued at $3,477,720. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jacob A. Orville sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $75.00, for a total transaction of $375,000.00. Following the transaction, the executive vice president owned 23,237 shares in the company, valued at approximately $1,742,775. The trade was a 17.71% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 9,858 shares of company stock valued at $695,289. 1.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wolfe Research downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Guggenheim downgraded Exact Sciences from a “buy” rating to a “neutral” rating in a research note on Thursday. Evercore ISI raised their price objective on Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a report on Wednesday, October 8th. Finally, TD Cowen increased their price target on Exact Sciences from $74.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Exact Sciences presently has an average rating of “Hold” and an average target price of $80.88.

Exact Sciences Price Performance

NASDAQ EXAS opened at $100.90 on Monday. The stock has a 50-day simple moving average of $62.85 and a 200 day simple moving average of $55.47. Exact Sciences Corporation has a twelve month low of $38.81 and a twelve month high of $101.87. The stock has a market capitalization of $19.12 billion, a PE ratio of -18.58, a P/E/G ratio of 5.56 and a beta of 1.34. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The firm had revenue of $850.74 million for the quarter, compared to analyst estimates of $810.42 million. During the same quarter last year, the firm posted ($0.21) EPS. The company’s revenue was up 20.0% on a year-over-year basis. Exact Sciences has set its FY 2025 guidance at EPS. Research analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.